Physician

Amy K Reisenauer, MD

According to 2025 Medicare claims, Amy Reisenauer, MD (NPI: 1104927110) practices dermatology in the Kahului-Wailuku, HI market, with the plurality of this provider's patient population coming from Maui, HI. This provider's primary affiliated billing organization is AMY REISENAUER MD LLC (NPI: 1922550987; TIN: 811348437) and primary practice location at 96753-6945.

Reisenauer's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,198 traditional Medicare patients, billed 8,555 HCPCS/CPT codes, and received $368,756 in Medicare payments. The top billing code was 11102 (Biopsy of related skin growth, first growth). Part D data shows 1,174 prescription claims across 428 beneficiaries totaling $319,627 in drug costs, led by Taltz Autoinjector (Ixekizumab). Open Payments data shows 22 records totaling $388. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,782 to $368,756. Similarly, Part D prescription costs have moved sharply higher in recent years, from $159,471 to $319,627. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$199K$399K2016 Medicare payment: $2,782 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $61,475 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $186,390 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $251,997 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $262,797 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $333,252 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $323,872 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $398,535 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $368,756 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
20161594$2,782
20172341,292$61,475
20186564,459$186,390
20197505,305$251,997
20207236,152$262,797
20218417,446$333,252
20221,1287,931$323,872
20231,2709,568$398,535
20241,1988,555$368,756

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$160K$320K2015 Drug cost: $159,471 (USD; Tot_Drug_Cst)2016 Drug cost: $186,543 (USD; Tot_Drug_Cst)2017 Drug cost: $105,585 (USD; Tot_Drug_Cst)2018 Drug cost: $144,227 (USD; Tot_Drug_Cst)2019 Drug cost: $130,416 (USD; Tot_Drug_Cst)2020 Drug cost: $124,849 (USD; Tot_Drug_Cst)2021 Drug cost: $152,829 (USD; Tot_Drug_Cst)2022 Drug cost: $141,951 (USD; Tot_Drug_Cst)2023 Drug cost: $258,678 (USD; Tot_Drug_Cst)2024 Drug cost: $319,627 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015288710$159,471
2016334891$186,543
2017279703$105,585
2018338884$144,227
2019355968$130,416
20203591,057$124,849
2021355918$152,829
2022387988$141,951
20234821,267$258,678
20244281,174$319,627

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
11102Biopsy of related skin growth, first growth369498$72
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more7171,008$61
88305Pathology examination of tissue using a microscope, intermediate complexity8512,512$51
17000Destruction of precancer skin growth, 1 growth476636$36
17003Destruction of precancer skin growth, 2-14 growths4032,518$5

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Taltz AutoinjectorIxekizumab13364$97,254
TacrolimusTacrolimus23810$4,250
FluorouracilFluorouracil601,949$3,828
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc441,521$3,344
ValacyclovirValacyclovir Hcl481,085$2,332

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.22$388ABBVIE INC.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Amy K. Reisenauer, MD?

Tedicare shows public-source Medicare data for Amy K. Reisenauer, MD (NPI 1104927110), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Amy K. Reisenauer, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Amy K. Reisenauer, MD?

Amy K. Reisenauer, MD is linked to AMY REISENAUER MD LLC (billing NPI 1922550987) in the available physician profile data.

Does Amy K. Reisenauer, MD have Open Payments data?

Amy K. Reisenauer, MD has 22 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.